{"success":true,"data":{"pressRelease":{"id":"161994","rtpr_id":"nGNX1PJRmt-20261006","ticker":"AXGN","exchange":"NASDAQ","all_tickers":["AXGN","CNXU","LLY","SOLV","VCEL"],"title":"Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.","author":"Globe Newswire","published_at":"2026-10-06T13:06:00.117Z","article_body":"RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor\n(https://www.globenewswire.com/Tracker?data=LN0ttO5_xFVbYAwIz1KGoAdzwWUAq-M_oyUxYmhkTbtvnSkoYhWP5gwZZdIyqbJcoGEvX78uP16Xp05EyJZmGw==)\nNews Commentary - The global advanced wound care market is valued at $13.37\nbillion in 2025 and is projected to reach $19.32 billion by 2030, a compound\nannual growth rate of 7.6%, according to MarketsandMarkets. The firm points to\nchronic disease, an aging population and traumatic injuries as the main\ndrivers, noting that diabetic foot ulcers affect roughly a quarter of patients\nwith diabetes and are a leading cause of hospitalization. Active Companies\nfrom around the markets with current developments this week include: Conexeu\nSciences Inc. (Nasdaq: CNXU), Solventum Corporation (NYSE: SOLV), Vericel\nCorporation (Nasdaq: VCEL), Axogen, Inc. (Nasdaq: AXGN), Eli Lilly and Company\n(NYSE: LLY).\n\nNorth America holds the largest share of that market today, according to the\nsame report, which also credits strengthened reimbursement frameworks with\nsupporting broader adoption of advanced therapies. The category spans negative\npressure wound therapy, advanced dressings, skin substitutes and biologic\nmatrices, and the large players in it are reporting steady growth.\n\nSome of the hardest cases remain difficult because of their shape. Deep tissue\nopenings left after skin cancer removal, surgical wounds that have split back\nopen, burns, and wounds that tunnel beneath the skin are irregular, and\nsheets, meshes and powders may not fully reach every surface. That gap has\ndrawn developers toward materials that can be applied as a liquid and then set\nin place.\n\nFor a medical device developer, the route to market for that kind of product\noften runs through the FDA’s 510(k) premarket notification pathway, which\nrequires a company to show its device is substantially equivalent to one\nalready legally marketed in the U.S. The FDA’s performance goal is a\ndecision within 90 days of active review, and the pathway is generally shorter\nthan the premarket approval process for higher-risk devices. Getting there\ndepends on manufacturing that is controlled and reproducible, which is where\none Nasdaq-listed developer just reported progress.\n\nConexeu Sciences Inc. (Nasdaq: CNXU) Advances Ten Minute Tissue™ Toward\nPlanned FDA 510(k) Submission\n* Planned FDA 510(k) submission for Ten Minute Tissue™ remains on track for\nthe first calendar quarter of 2027\n* Multiple scaled-up batches of CXU™ material met predefined Company\nspecifications for key material characteristics and product performance\n* Expanded production of representative test samples to support preclinical,\nbiocompatibility, chemical characterization, stability and other regulatory\ntesting\n* FDA feedback received through the Q-Submission process is being incorporated\ninto development and regulatory planning\n* Workstreams running in parallel where appropriate, using test materials made\nwith the controlled manufacturing process\nConexeu Sciences Inc. (Nasdaq: CNXU)\n(https://www.globenewswire.com/Tracker?data=msZoR7d4p8erV1gCOzAlJkYV81_Sb06msIJnKEP486qu-xTRlDaWz3Bky_78NdZ5MpA-I4e3vZLmrd84u0VVkSG9S99C-rFx_avIp5-6TU-hYIBsM47pfSvoMahdLELn),\na preclinical-stage medical device and regenerative medicine company advancing\nCXU™, an investigational extracellular matrix platform designed to support\ntissue restoration, has provided an update on the regulatory and manufacturing\nprogram supporting its planned FDA 510(k) premarket notification for Ten\nMinute Tissue™, its lead wound care device candidate. The Company says it\nremains on track to make the submission in the first calendar quarter of 2027.\n\nFollowing process-development work, multiple scaled-up batches of CXU™\nmaterial met predefined Company specifications for key material\ncharacteristics and product performance measures. Conexeu views manufacturing\nscale-up as a key stage in the transition of Ten Minute Tissue™ from a\ndevelopment-stage product candidate toward a potential commercial product,\nsupporting both the representative materials needed for regulatory testing and\nthe supply capabilities intended to meet future demand, subject to FDA\nclearance.\n\n“We have moved from process development to implementing a controlled\nmanufacturing process,” said Miles Harrison, President and CEO of Conexeu.\n“That progress is important for two reasons. First, it supports the\nregulatory testing required to advance our planned FDA 510(k) submission.\nSecond, it moves us closer to establishing the scalable manufacturing\ninfrastructure needed to support commercialization. We believe manufacturing\nscale-up is one of the critical bridges between regulatory development and our\nability to ultimately bring our lead device to market.”\n\nThe Company’s current program covers manufacturing process development and\nscale-up, production of representative test samples made to reflect the final\nproduct, and progress toward commercial manufacturing readiness, including\nsupplier relationships and production capabilities. Alongside that, Conexeu is\nadvancing a preclinical wound model study program, including pilot studies,\nintended to generate data supporting substantial equivalence to an identified\npredicate device, together with biocompatibility, chemical characterization,\nsterilization, packaging and stability work.\n\n“Wherever appropriate, we are running these workstreams at the same time\nrather than one after another, using representative test materials made with\nour controlled manufacturing process,” said Brian Pilcher, Ph.D., Chief\nMedical Officer of Conexeu. “This approach keeps our planned first-quarter\n2027 submission on track while maintaining the consistency that regulatory\ntesting requires.”\n\nTen Minute Tissue™ is built on the CXU™ platform, which is based on the\nextracellular matrix, the natural framework that holds the body’s tissues\ntogether. Conexeu plans to focus its commercial strategy on wound care, where\nit believes two features set the device candidate apart: it can be applied as\na liquid, and it is designed to turn into a gel at body temperature within\nabout ten minutes. Because it is designed to flow into place and then set, it\nis intended to fill gaps and channels in irregularly shaped wounds and to act\nas a scaffold that the body’s own cells can move into.\n\nConexeu Sciences Inc. (Nasdaq: CNXU) is a preclinical-stage medical device and\nregenerative medicine company. Its patented extracellular matrix platform,\nCXU™, is designed to support bioregeneration and is protected by patents\nissued in the U.S., EU, Japan and Australia, with a patent pending in Canada,\nwith the Company holding all rights, title and interest and no royalty or\nlicensing obligations. Conexeu is targeting markets including wound care,\nperiodontal applications, and facial and body tissue restoration, a category\nwhere the success of GLP-1 weight-loss therapies is creating new demand.\n\nCONTINUED... Read this and more news for Conexeu Sciences Inc. (Nasdaq: CNXU)\nat: wsi.news\n(https://www.globenewswire.com/Tracker?data=OSUbmYXhLqkyWhVfnV0YJpIPabkJdIKMTbzObKwEHLSun-j4BlScewSK-UTJJQPuZLiOqsFRRPGYhezXvya0wQ==)\n\nIn other industry developments and happenings in the market this week include:\n\nSolventum Corporation (NYSE: SOLV)\n\nSolventum, whose MedSurg business includes negative pressure wound therapy and\nadvanced dressings, reported second quarter 2026 sales of $2.2 billion, with\norganic growth of 9.5%. Advanced Wound Care sales were $537 million, up 14.9%\nas reported and 7.1% organically, within a MedSurg segment that grew 12.7% to\n$1.372 billion.\n\nAdjusted diluted EPS rose 50.9% to $2.55, and the company raised its full-year\n2026 guidance, lifting organic sales growth to 2.5% to 3.0% and adjusted EPS\nto $7.10 to $7.20.\n\nVericel Corporation (Nasdaq: VCEL)\n\nVericel, which markets the Epicel® and NexoBrid® burn care products\nalongside its MACI® cartilage repair implant, reported second quarter 2026\ntotal revenue of $77.5 million, up 22%, with Burn Care revenue of $12.0\nmillion, up 22%, and MACI revenue of $65.5 million, up 23%. The company\nreported net income of $2.2 million and raised its full-year revenue guidance\nto $330 million to $340 million, including Burn Care revenue of $46 million to\n$50 million.\n\n“The Company delivered excellent financial and business results in the\nsecond quarter as we continue to generate top-tier revenue and profit growth\nas well as significant free cash flow,” said CEO Nick Colangelo. Vericel\nalso authorized a $200 million share repurchase program.\n\nAxogen, Inc. (Nasdaq: AXGN)\n\nAxogen, a developer of technologies for peripheral nerve regeneration and\nrepair, reported second quarter 2026 revenue of $69.7 million, up 23.1%, with\nits Breast segment growing more than 50% year over year. The company raised\nfull-year 2026 revenue guidance to at least $279 million, or growth of at\nleast 24%, and expects gross margin of at least 73% and positive free cash\nflow.\n\n“We are pleased with our second-quarter revenue performance and the progress\nwe’re making across each of Axogen’s strategic plan priorities,” said\nMichael Dale, President and CEO.\n\nEli Lilly and Company (NYSE: LLY)\n\nLilly, whose GLP-1 medicines are reshaping the weight-loss market and creating\nnew demand in adjacent aesthetic markets, reported second quarter 2026 revenue\nof $23.0 billion, up 48%. Mounjaro® revenue reached $9.9 billion, up 91%, and\nZepbound® revenue reached $4.9 billion, up 46%. The company raised its\nfull-year 2026 revenue guidance to $85.0 billion to $87.0 billion.\n\n“Lilly’s momentum continues, as we delivered 48% revenue growth and raised\nour full-year guidance. At the same time, Lilly is building for the future,”\nsaid Chair and CEO David A. Ricks.\n\nUnderstand Any Stock in 30 Seconds\n\nWeighing a sector this busy means piecing together prices, financials, news\nand analyst views across a dozen tabs. Luxor IQ by Quote Daddy does that in\none step. Enter a U.S. ticker and it turns live prices, a year of trend data,\nfundamentals, news and analyst ratings into a clear research note written by\nAI, covering valuation, financial health and key risks. You can run three\nreports a day free on the web or in the Quote Daddy app. Try it at\nai.quotedaddy.com\n(https://www.globenewswire.com/Tracker?data=K91SeXEbfvzgdt246BDObt15D8UGrslpgLnyz0h27xz6CF-P06mACWmwZWhZZFQiIucl-Z3vPYyrVmkHGwfXsrxBhMf5RTHsDpIkNyg-DAk=).\n\nContact Information:\n\nwsi.news\n(https://www.globenewswire.com/Tracker?data=OSUbmYXhLqkyWhVfnV0YJtgYIwruDLdvYQ1NLsOFJfEOKoOtIzLljJ_cN6x5_VNmaz-WLPhldRJ0q8okHxMBDQ==)\n\nMedia Contact: info@wsi.news\n\nDISCLAIMER: Nothing in this publication should be considered as personalized\nfinancial advice. We are not licensed under securities laws to address your\nparticular financial situation. No communication by our employees to you\nshould be deemed as personalized financial advice. Please consult a licensed\nfinancial advisor before making any investment decision. This is a paid\nadvertisement and is neither an offer nor recommendation to buy or sell any\nsecurity. We hold no investment licenses and are thus neither licensed nor\nqualified to provide investment advice. The content in this report or email is\nnot provided to any individual with a view toward their individual\ncircumstances.\n\nThis article is being distributed by Wall Street Investor (wsi.news), a\nproperty of a joint venture between Market Equities Limited, a company\nincorporated under the laws of Ireland (“MEL”), and Mining Stock, LLC, a\nTennessee limited liability company (“Mining Stock”), under which MEL and\nMining Stock share in the net profits of the joint venture. MEL has been paid\na fee for Conexeu Sciences Inc. advertising and digital media from Creative\nDirect Marketing Group (“CDMG”), and compensation received in connection\nwith this article may be shared with Mining Stock under the terms of the joint\nventure. MEL has not been paid a fee directly by Conexeu Sciences Inc., and\nMEL is not affiliated with, and is a separate and independent entity from,\nCDMG and Conexeu Sciences Inc. MEL also expects to receive further\ncompensation as part of an ongoing digital media effort to increase visibility\nfor the company. No further notice will be given, but let this disclaimer\nserve as notice that all material, including this article, has been reviewed\nand approved by Conexeu Sciences Inc. and CDMG.\n\nThis compensation constitutes a conflict of interest as to our ability to\nremain objective in our communication regarding the profiled company. Because\nof this conflict, individuals are strongly encouraged to not use this\npublication as the basis for any investment decision.\n\nQuote Daddy Disclosure. Quote Daddy, including its Luxor IQ research tool, is\na stock-tracking application affiliated with MEL, and this reference\nconstitutes promotion of an affiliated product. Quote Daddy is not a\nbroker-dealer, and nothing in the application or in this article is financial,\ninvestment, tax, or legal advice. Market data provided in the application is\nfor informational purposes only and may be delayed. Any in-app commentary or\nbriefing content is educational only. Luxor IQ reports are generated by\nartificial intelligence, may contain errors, and are for informational and\neducational purposes only. Always do your own research before making any\ninvestment decision.\n\nMEL and its owners, operators, directors, and affiliates do not own any shares\nof Conexeu Sciences Inc., but reserve the right to buy and sell shares of\nConexeu Sciences Inc. at any time without any further notice commencing\nimmediately and ongoing, in the open market, through private placements,\nand/or through other investment vehicles. Mining Stock and its principals may,\nfrom time to time, hold positions in securities mentioned in this article.\nThere may also be third parties who hold shares of Conexeu Sciences Inc. and\nmay liquidate their shares, which could have a negative effect on the price of\nthe stock.\n\nWhile all information is believed to be reliable, it is not guaranteed by us\nto be accurate. Individuals should assume that all information contained in\nthis publication is not trustworthy unless verified by their own independent\nresearch. Also, because events and circumstances frequently do not occur as\nexpected, there will likely be differences between any predictions and actual\nresults. Always consult a licensed investment professional before making any\ninvestment decision. Be extremely careful: investing in securities carries a\nhigh degree of risk, and you may lose some or all of your investment.\n\nReferences to Solventum Corporation, Vericel Corporation, Axogen, Inc. and Eli\nLilly and Company are provided solely as market and sector context. Those\ncompanies are not peers, competitors, or financial comparables of Conexeu\nSciences Inc., none of them is involved in this article, and their commercial\nproducts, results, scale and share performance are not indicative of Conexeu\nSciences Inc.’s prospects. Conexeu Sciences Inc. has no products cleared for\nsale and no product revenue. No partnership, affiliation, or endorsement is\nimplied. Market-size figures cited are third-party projections for the\nadvanced wound care market as a whole and do not represent revenue addressable\nby, or attributable to, any company named in this article.\n\nCautionary Note Regarding Investigational Devices and Preclinical Results. Ten\nMinute Tissue™ and the CXU™ platform are investigational and have not been\ncleared or approved by the U.S. Food and Drug Administration or any other\nregulator. All studies cited in support of the platform are preclinical, and\npreclinical results are not necessarily predictive of clinical outcomes.\nAccording to the Company, none of the cited studies evaluated CXU™\nspecifically in the wound care indications described, and supporting evidence\nin indication-specific preclinical models is being developed. The\nmanufacturing specifications referenced are the Company’s own predefined\nspecifications. FDA feedback received through the Q-Submission process is\nadvisory and does not indicate that clearance will be granted. The planned\nfirst-quarter 2027 510(k) submission is a target, and there is no assurance it\nwill be made on that timeline, accepted, or cleared.\n\nForward-Looking Statements: This publication contains forward-looking\nstatements within the meaning of Section 27A of the Securities Act of 1933, as\namended, and Section 21E of the Securities Exchange Act of 1934, as amended,\nand such forward-looking statements are made pursuant to the safe harbor\nprovisions of the Private Securities Litigation Reform Act of 1995.\nForward-looking statements describe future expectations, plans, results, or\nstrategies and are generally preceded by words such as “may”,\n“future”, “plan” or “planned”, “will” or “should”,\n“expected”, “anticipates”, “draft”, “eventually” or\n“projected”. You are cautioned that such statements are subject to a\nmultitude of risks and uncertainties that could cause future circumstances,\nevents, or results to differ materially from those projected in the\nforward-looking statements, including the risks that actual results may differ\nmaterially from those projected in the forward-looking statements as a result\nof various factors, and other risks identified in a company’s annual report\non Form 10-K or 10-Q and other filings made by such company with the\nSecurities and Exchange Commission. You should consider these factors in\nevaluating the forward-looking statements included herein, and not place undue\nreliance on such statements. The forward-looking statements in this\npublication are made as of the date hereof and MEL undertakes no obligation to\nupdate such statements.\n\nTrademarks. CXU™, Ten Minute Tissue™ and Architecting Bioregeneration™\nare trademarks of Conexeu Sciences Inc. All other marks referenced in this\narticle are the property of their respective owners.\n\nSOURCE Wall Street Investor\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f935448d-1954-4e3f-bc5b-9256551a95ff)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1PJRmt-20261006","title":"Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.","author":"Globe Newswire","ticker":"AXGN","created":"2026-10-06T13:06:00.117Z","tickers":["AXGN","CNXU","LLY","SOLV","VCEL"],"exchange":"NASDAQ","article_body":"RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor\n(https://www.globenewswire.com/Tracker?data=LN0ttO5_xFVbYAwIz1KGoAdzwWUAq-M_oyUxYmhkTbtvnSkoYhWP5gwZZdIyqbJcoGEvX78uP16Xp05EyJZmGw==)\nNews Commentary - The global advanced wound care market is valued at $13.37\nbillion in 2025 and is projected to reach $19.32 billion by 2030, a compound\nannual growth rate of 7.6%, according to MarketsandMarkets. The firm points to\nchronic disease, an aging population and traumatic injuries as the main\ndrivers, noting that diabetic foot ulcers affect roughly a quarter of patients\nwith diabetes and are a leading cause of hospitalization. Active Companies\nfrom around the markets with current developments this week include: Conexeu\nSciences Inc. (Nasdaq: CNXU), Solventum Corporation (NYSE: SOLV), Vericel\nCorporation (Nasdaq: VCEL), Axogen, Inc. (Nasdaq: AXGN), Eli Lilly and Company\n(NYSE: LLY).\n\nNorth America holds the largest share of that market today, according to the\nsame report, which also credits strengthened reimbursement frameworks with\nsupporting broader adoption of advanced therapies. The category spans negative\npressure wound therapy, advanced dressings, skin substitutes and biologic\nmatrices, and the large players in it are reporting steady growth.\n\nSome of the hardest cases remain difficult because of their shape. Deep tissue\nopenings left after skin cancer removal, surgical wounds that have split back\nopen, burns, and wounds that tunnel beneath the skin are irregular, and\nsheets, meshes and powders may not fully reach every surface. That gap has\ndrawn developers toward materials that can be applied as a liquid and then set\nin place.\n\nFor a medical device developer, the route to market for that kind of product\noften runs through the FDA’s 510(k) premarket notification pathway, which\nrequires a company to show its device is substantially equivalent to one\nalready legally marketed in the U.S. The FDA’s performance goal is a\ndecision within 90 days of active review, and the pathway is generally shorter\nthan the premarket approval process for higher-risk devices. Getting there\ndepends on manufacturing that is controlled and reproducible, which is where\none Nasdaq-listed developer just reported progress.\n\nConexeu Sciences Inc. (Nasdaq: CNXU) Advances Ten Minute Tissue™ Toward\nPlanned FDA 510(k) Submission\n* Planned FDA 510(k) submission for Ten Minute Tissue™ remains on track for\nthe first calendar quarter of 2027\n* Multiple scaled-up batches of CXU™ material met predefined Company\nspecifications for key material characteristics and product performance\n* Expanded production of representative test samples to support preclinical,\nbiocompatibility, chemical characterization, stability and other regulatory\ntesting\n* FDA feedback received through the Q-Submission process is being incorporated\ninto development and regulatory planning\n* Workstreams running in parallel where appropriate, using test materials made\nwith the controlled manufacturing process\nConexeu Sciences Inc. (Nasdaq: CNXU)\n(https://www.globenewswire.com/Tracker?data=msZoR7d4p8erV1gCOzAlJkYV81_Sb06msIJnKEP486qu-xTRlDaWz3Bky_78NdZ5MpA-I4e3vZLmrd84u0VVkSG9S99C-rFx_avIp5-6TU-hYIBsM47pfSvoMahdLELn),\na preclinical-stage medical device and regenerative medicine company advancing\nCXU™, an investigational extracellular matrix platform designed to support\ntissue restoration, has provided an update on the regulatory and manufacturing\nprogram supporting its planned FDA 510(k) premarket notification for Ten\nMinute Tissue™, its lead wound care device candidate. The Company says it\nremains on track to make the submission in the first calendar quarter of 2027.\n\nFollowing process-development work, multiple scaled-up batches of CXU™\nmaterial met predefined Company specifications for key material\ncharacteristics and product performance measures. Conexeu views manufacturing\nscale-up as a key stage in the transition of Ten Minute Tissue™ from a\ndevelopment-stage product candidate toward a potential commercial product,\nsupporting both the representative materials needed for regulatory testing and\nthe supply capabilities intended to meet future demand, subject to FDA\nclearance.\n\n“We have moved from process development to implementing a controlled\nmanufacturing process,” said Miles Harrison, President and CEO of Conexeu.\n“That progress is important for two reasons. First, it supports the\nregulatory testing required to advance our planned FDA 510(k) submission.\nSecond, it moves us closer to establishing the scalable manufacturing\ninfrastructure needed to support commercialization. We believe manufacturing\nscale-up is one of the critical bridges between regulatory development and our\nability to ultimately bring our lead device to market.”\n\nThe Company’s current program covers manufacturing process development and\nscale-up, production of representative test samples made to reflect the final\nproduct, and progress toward commercial manufacturing readiness, including\nsupplier relationships and production capabilities. Alongside that, Conexeu is\nadvancing a preclinical wound model study program, including pilot studies,\nintended to generate data supporting substantial equivalence to an identified\npredicate device, together with biocompatibility, chemical characterization,\nsterilization, packaging and stability work.\n\n“Wherever appropriate, we are running these workstreams at the same time\nrather than one after another, using representative test materials made with\nour controlled manufacturing process,” said Brian Pilcher, Ph.D., Chief\nMedical Officer of Conexeu. “This approach keeps our planned first-quarter\n2027 submission on track while maintaining the consistency that regulatory\ntesting requires.”\n\nTen Minute Tissue™ is built on the CXU™ platform, which is based on the\nextracellular matrix, the natural framework that holds the body’s tissues\ntogether. Conexeu plans to focus its commercial strategy on wound care, where\nit believes two features set the device candidate apart: it can be applied as\na liquid, and it is designed to turn into a gel at body temperature within\nabout ten minutes. Because it is designed to flow into place and then set, it\nis intended to fill gaps and channels in irregularly shaped wounds and to act\nas a scaffold that the body’s own cells can move into.\n\nConexeu Sciences Inc. (Nasdaq: CNXU) is a preclinical-stage medical device and\nregenerative medicine company. Its patented extracellular matrix platform,\nCXU™, is designed to support bioregeneration and is protected by patents\nissued in the U.S., EU, Japan and Australia, with a patent pending in Canada,\nwith the Company holding all rights, title and interest and no royalty or\nlicensing obligations. Conexeu is targeting markets including wound care,\nperiodontal applications, and facial and body tissue restoration, a category\nwhere the success of GLP-1 weight-loss therapies is creating new demand.\n\nCONTINUED... Read this and more news for Conexeu Sciences Inc. (Nasdaq: CNXU)\nat: wsi.news\n(https://www.globenewswire.com/Tracker?data=OSUbmYXhLqkyWhVfnV0YJpIPabkJdIKMTbzObKwEHLSun-j4BlScewSK-UTJJQPuZLiOqsFRRPGYhezXvya0wQ==)\n\nIn other industry developments and happenings in the market this week include:\n\nSolventum Corporation (NYSE: SOLV)\n\nSolventum, whose MedSurg business includes negative pressure wound therapy and\nadvanced dressings, reported second quarter 2026 sales of $2.2 billion, with\norganic growth of 9.5%. Advanced Wound Care sales were $537 million, up 14.9%\nas reported and 7.1% organically, within a MedSurg segment that grew 12.7% to\n$1.372 billion.\n\nAdjusted diluted EPS rose 50.9% to $2.55, and the company raised its full-year\n2026 guidance, lifting organic sales growth to 2.5% to 3.0% and adjusted EPS\nto $7.10 to $7.20.\n\nVericel Corporation (Nasdaq: VCEL)\n\nVericel, which markets the Epicel® and NexoBrid® burn care products\nalongside its MACI® cartilage repair implant, reported second quarter 2026\ntotal revenue of $77.5 million, up 22%, with Burn Care revenue of $12.0\nmillion, up 22%, and MACI revenue of $65.5 million, up 23%. The company\nreported net income of $2.2 million and raised its full-year revenue guidance\nto $330 million to $340 million, including Burn Care revenue of $46 million to\n$50 million.\n\n“The Company delivered excellent financial and business results in the\nsecond quarter as we continue to generate top-tier revenue and profit growth\nas well as significant free cash flow,” said CEO Nick Colangelo. Vericel\nalso authorized a $200 million share repurchase program.\n\nAxogen, Inc. (Nasdaq: AXGN)\n\nAxogen, a developer of technologies for peripheral nerve regeneration and\nrepair, reported second quarter 2026 revenue of $69.7 million, up 23.1%, with\nits Breast segment growing more than 50% year over year. The company raised\nfull-year 2026 revenue guidance to at least $279 million, or growth of at\nleast 24%, and expects gross margin of at least 73% and positive free cash\nflow.\n\n“We are pleased with our second-quarter revenue performance and the progress\nwe’re making across each of Axogen’s strategic plan priorities,” said\nMichael Dale, President and CEO.\n\nEli Lilly and Company (NYSE: LLY)\n\nLilly, whose GLP-1 medicines are reshaping the weight-loss market and creating\nnew demand in adjacent aesthetic markets, reported second quarter 2026 revenue\nof $23.0 billion, up 48%. Mounjaro® revenue reached $9.9 billion, up 91%, and\nZepbound® revenue reached $4.9 billion, up 46%. The company raised its\nfull-year 2026 revenue guidance to $85.0 billion to $87.0 billion.\n\n“Lilly’s momentum continues, as we delivered 48% revenue growth and raised\nour full-year guidance. At the same time, Lilly is building for the future,”\nsaid Chair and CEO David A. Ricks.\n\nUnderstand Any Stock in 30 Seconds\n\nWeighing a sector this busy means piecing together prices, financials, news\nand analyst views across a dozen tabs. Luxor IQ by Quote Daddy does that in\none step. Enter a U.S. ticker and it turns live prices, a year of trend data,\nfundamentals, news and analyst ratings into a clear research note written by\nAI, covering valuation, financial health and key risks. You can run three\nreports a day free on the web or in the Quote Daddy app. Try it at\nai.quotedaddy.com\n(https://www.globenewswire.com/Tracker?data=K91SeXEbfvzgdt246BDObt15D8UGrslpgLnyz0h27xz6CF-P06mACWmwZWhZZFQiIucl-Z3vPYyrVmkHGwfXsrxBhMf5RTHsDpIkNyg-DAk=).\n\nContact Information:\n\nwsi.news\n(https://www.globenewswire.com/Tracker?data=OSUbmYXhLqkyWhVfnV0YJtgYIwruDLdvYQ1NLsOFJfEOKoOtIzLljJ_cN6x5_VNmaz-WLPhldRJ0q8okHxMBDQ==)\n\nMedia Contact: info@wsi.news\n\nDISCLAIMER: Nothing in this publication should be considered as personalized\nfinancial advice. We are not licensed under securities laws to address your\nparticular financial situation. No communication by our employees to you\nshould be deemed as personalized financial advice. Please consult a licensed\nfinancial advisor before making any investment decision. This is a paid\nadvertisement and is neither an offer nor recommendation to buy or sell any\nsecurity. We hold no investment licenses and are thus neither licensed nor\nqualified to provide investment advice. The content in this report or email is\nnot provided to any individual with a view toward their individual\ncircumstances.\n\nThis article is being distributed by Wall Street Investor (wsi.news), a\nproperty of a joint venture between Market Equities Limited, a company\nincorporated under the laws of Ireland (“MEL”), and Mining Stock, LLC, a\nTennessee limited liability company (“Mining Stock”), under which MEL and\nMining Stock share in the net profits of the joint venture. MEL has been paid\na fee for Conexeu Sciences Inc. advertising and digital media from Creative\nDirect Marketing Group (“CDMG”), and compensation received in connection\nwith this article may be shared with Mining Stock under the terms of the joint\nventure. MEL has not been paid a fee directly by Conexeu Sciences Inc., and\nMEL is not affiliated with, and is a separate and independent entity from,\nCDMG and Conexeu Sciences Inc. MEL also expects to receive further\ncompensation as part of an ongoing digital media effort to increase visibility\nfor the company. No further notice will be given, but let this disclaimer\nserve as notice that all material, including this article, has been reviewed\nand approved by Conexeu Sciences Inc. and CDMG.\n\nThis compensation constitutes a conflict of interest as to our ability to\nremain objective in our communication regarding the profiled company. Because\nof this conflict, individuals are strongly encouraged to not use this\npublication as the basis for any investment decision.\n\nQuote Daddy Disclosure. Quote Daddy, including its Luxor IQ research tool, is\na stock-tracking application affiliated with MEL, and this reference\nconstitutes promotion of an affiliated product. Quote Daddy is not a\nbroker-dealer, and nothing in the application or in this article is financial,\ninvestment, tax, or legal advice. Market data provided in the application is\nfor informational purposes only and may be delayed. Any in-app commentary or\nbriefing content is educational only. Luxor IQ reports are generated by\nartificial intelligence, may contain errors, and are for informational and\neducational purposes only. Always do your own research before making any\ninvestment decision.\n\nMEL and its owners, operators, directors, and affiliates do not own any shares\nof Conexeu Sciences Inc., but reserve the right to buy and sell shares of\nConexeu Sciences Inc. at any time without any further notice commencing\nimmediately and ongoing, in the open market, through private placements,\nand/or through other investment vehicles. Mining Stock and its principals may,\nfrom time to time, hold positions in securities mentioned in this article.\nThere may also be third parties who hold shares of Conexeu Sciences Inc. and\nmay liquidate their shares, which could have a negative effect on the price of\nthe stock.\n\nWhile all information is believed to be reliable, it is not guaranteed by us\nto be accurate. Individuals should assume that all information contained in\nthis publication is not trustworthy unless verified by their own independent\nresearch. Also, because events and circumstances frequently do not occur as\nexpected, there will likely be differences between any predictions and actual\nresults. Always consult a licensed investment professional before making any\ninvestment decision. Be extremely careful: investing in securities carries a\nhigh degree of risk, and you may lose some or all of your investment.\n\nReferences to Solventum Corporation, Vericel Corporation, Axogen, Inc. and Eli\nLilly and Company are provided solely as market and sector context. Those\ncompanies are not peers, competitors, or financial comparables of Conexeu\nSciences Inc., none of them is involved in this article, and their commercial\nproducts, results, scale and share performance are not indicative of Conexeu\nSciences Inc.’s prospects. Conexeu Sciences Inc. has no products cleared for\nsale and no product revenue. No partnership, affiliation, or endorsement is\nimplied. Market-size figures cited are third-party projections for the\nadvanced wound care market as a whole and do not represent revenue addressable\nby, or attributable to, any company named in this article.\n\nCautionary Note Regarding Investigational Devices and Preclinical Results. Ten\nMinute Tissue™ and the CXU™ platform are investigational and have not been\ncleared or approved by the U.S. Food and Drug Administration or any other\nregulator. All studies cited in support of the platform are preclinical, and\npreclinical results are not necessarily predictive of clinical outcomes.\nAccording to the Company, none of the cited studies evaluated CXU™\nspecifically in the wound care indications described, and supporting evidence\nin indication-specific preclinical models is being developed. The\nmanufacturing specifications referenced are the Company’s own predefined\nspecifications. FDA feedback received through the Q-Submission process is\nadvisory and does not indicate that clearance will be granted. The planned\nfirst-quarter 2027 510(k) submission is a target, and there is no assurance it\nwill be made on that timeline, accepted, or cleared.\n\nForward-Looking Statements: This publication contains forward-looking\nstatements within the meaning of Section 27A of the Securities Act of 1933, as\namended, and Section 21E of the Securities Exchange Act of 1934, as amended,\nand such forward-looking statements are made pursuant to the safe harbor\nprovisions of the Private Securities Litigation Reform Act of 1995.\nForward-looking statements describe future expectations, plans, results, or\nstrategies and are generally preceded by words such as “may”,\n“future”, “plan” or “planned”, “will” or “should”,\n“expected”, “anticipates”, “draft”, “eventually” or\n“projected”. You are cautioned that such statements are subject to a\nmultitude of risks and uncertainties that could cause future circumstances,\nevents, or results to differ materially from those projected in the\nforward-looking statements, including the risks that actual results may differ\nmaterially from those projected in the forward-looking statements as a result\nof various factors, and other risks identified in a company’s annual report\non Form 10-K or 10-Q and other filings made by such company with the\nSecurities and Exchange Commission. You should consider these factors in\nevaluating the forward-looking statements included herein, and not place undue\nreliance on such statements. The forward-looking statements in this\npublication are made as of the date hereof and MEL undertakes no obligation to\nupdate such statements.\n\nTrademarks. CXU™, Ten Minute Tissue™ and Architecting Bioregeneration™\nare trademarks of Conexeu Sciences Inc. All other marks referenced in this\narticle are the property of their respective owners.\n\nSOURCE Wall Street Investor\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f935448d-1954-4e3f-bc5b-9256551a95ff)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-06T13:06:00.171516837Z","server_sent_at_ms":1791291960171},"received_at":"2026-10-06T13:06:00.341Z","source_url":null},"analysis":{"id":"150499","press_release_id":"161994","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Article is a paid advertisement — Conexeu content was reviewed and approved by the company and its paid marketer CDMG","Publisher holds no licenses and discloses a conflict of interest; reserves right to trade profiled stock","Axogen's results are used as promotional context with explicit disclaimer that named companies are not comparables of the profiled company","Profiled company CNXU is preclinical with no cleared products or revenue"],"eventType":"operations_update","narrative":"This GlobeNewswire item is a paid promotional commentary by Wall Street Investor whose featured subject is Conexeu Sciences (CNXU), not the filer Axogen.\n\nAxogen appears only as sector context: Q2 2026 revenue of $69.7 million, up 23.1%, with Breast segment growth above 50% and FY2026 guidance raised to at least $279 million.\n\nThe disclaimer confirms the publisher was compensated to promote Conexeu and that Axogen and other named companies are 'not peers, competitors, or financial comparables' and not involved in the article.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Paid promotional piece centered on CNXU; AXGN data is stale sector context — suppress or treat as marketing, not news."},"keyFigures":{"revenue":"$69.7 million","guidance":"FY2026 revenue raised to at least $279 million (at least 24% growth), gross margin at least 73%, positive free cash flow","revenueYoy":"23.1%","customDimensions":{"breast_segment_growth":"more than 50% YoY"}},"namedEntities":{"people":[{"name":"Michael Dale","role":"President and CEO of Axogen"},{"name":"Miles Harrison","role":"President and CEO of Conexeu Sciences"},{"name":"Brian Pilcher, Ph.D.","role":"Chief Medical Officer of Conexeu Sciences"},{"name":"Nick Colangelo","role":"CEO of Vericel"},{"name":"David A. Ricks","role":"Chair and CEO of Eli Lilly"}],"products":["Ten Minute Tissue™","CXU™","Epicel®","NexoBrid®","MACI®","Mounjaro®","Zepbound®"],"companies":[{"name":"Axogen, Inc.","ticker":"AXGN","relationship":"filer / sector context"},{"name":"Conexeu Sciences Inc.","ticker":"CNXU","relationship":"profiled company (subject of paid promotion)"},{"name":"Solventum Corporation","ticker":"SOLV","relationship":"mentioned"},{"name":"Vericel Corporation","ticker":"VCEL","relationship":"mentioned"},{"name":"Eli Lilly and Company","ticker":"LLY","relationship":"mentioned"},{"name":"Wall Street Investor (wsi.news)","relationship":"publisher of paid advertisement"},{"name":"Market Equities Limited","relationship":"publisher joint-venture partner, compensated"},{"name":"Mining Stock, LLC","relationship":"publisher joint-venture partner"},{"name":"Creative Direct Marketing Group","relationship":"paid promoter of Conexeu"},{"name":"Quote Daddy / Luxor IQ","relationship":"affiliated product promoted in article"},{"name":"MarketsandMarkets","relationship":"market research source"}],"dollarAmounts":[{"amount":"$13.37 billion","context":"global advanced wound care market value in 2025"},{"amount":"$19.32 billion","context":"projected wound care market value by 2030"},{"amount":"$69.7 million","context":"Axogen Q2 2026 revenue"},{"amount":"$279 million","context":"Axogen raised FY2026 revenue guidance floor"},{"amount":"$2.2 billion","context":"Solventum Q2 2026 sales"},{"amount":"$537 million","context":"Solventum Advanced Wound Care Q2 sales"},{"amount":"$77.5 million","context":"Vericel Q2 2026 revenue"},{"amount":"$200 million","context":"Vericel share repurchase authorization"},{"amount":"$23.0 billion","context":"Eli Lilly Q2 2026 revenue"},{"amount":"$85.0 billion to $87.0 billion","context":"Lilly raised FY2026 revenue guidance"}]},"materialImpact":{"score":2,"reasoning":"This is a paid promotional commentary piece whose primary subject is Conexeu Sciences (CNXU); AXGN's own Q2 results (revenue $69.7M, +23.1%, raised guidance) appear only as sector context and were presumably already disclosed. Sentiment for the filer is modestly positive on fundamentals, but the piece itself is marketing content, not an issuer disclosure."},"tickerRelevance":{"others":[{"ticker":"CNXU","relevance":"profiled company / subject of paid promotion"},{"ticker":"SOLV","relevance":"mentioned"},{"ticker":"VCEL","relevance":"mentioned"},{"ticker":"LLY","relevance":"mentioned"}],"primary":"AXGN"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":["earnings"],"importanceComponents":{"tickerTier":"small-cap","paidContent":true,"eventGravity":"paid-promotion-commentary","issuerAuthored":false}},"event_type":"operations_update","event_type_secondary":["earnings"],"sentiment":"neutral","material_impact_score":2,"narrative":"This GlobeNewswire item is a paid promotional commentary by Wall Street Investor whose featured subject is Conexeu Sciences (CNXU), not the filer Axogen.\n\nAxogen appears only as sector context: Q2 2026 revenue of $69.7 million, up 23.1%, with Breast segment growth above 50% and FY2026 guidance raised to at least $279 million.\n\nThe disclaimer confirms the publisher was compensated to promote Conexeu and that Axogen and other named companies are 'not peers, competitors, or financial comparables' and not involved in the article.","key_figures":{"revenue":"$69.7 million","guidance":"FY2026 revenue raised to at least $279 million (at least 24% growth), gross margin at least 73%, positive free cash flow","revenueYoy":"23.1%","customDimensions":{"breast_segment_growth":"more than 50% YoY"}},"named_entities":{"people":[{"name":"Michael Dale","role":"President and CEO of Axogen"},{"name":"Miles Harrison","role":"President and CEO of Conexeu Sciences"},{"name":"Brian Pilcher, Ph.D.","role":"Chief Medical Officer of Conexeu Sciences"},{"name":"Nick Colangelo","role":"CEO of Vericel"},{"name":"David A. Ricks","role":"Chair and CEO of Eli Lilly"}],"products":["Ten Minute Tissue™","CXU™","Epicel®","NexoBrid®","MACI®","Mounjaro®","Zepbound®"],"companies":[{"name":"Axogen, Inc.","ticker":"AXGN","relationship":"filer / sector context"},{"name":"Conexeu Sciences Inc.","ticker":"CNXU","relationship":"profiled company (subject of paid promotion)"},{"name":"Solventum Corporation","ticker":"SOLV","relationship":"mentioned"},{"name":"Vericel Corporation","ticker":"VCEL","relationship":"mentioned"},{"name":"Eli Lilly and Company","ticker":"LLY","relationship":"mentioned"},{"name":"Wall Street Investor (wsi.news)","relationship":"publisher of paid advertisement"},{"name":"Market Equities Limited","relationship":"publisher joint-venture partner, compensated"},{"name":"Mining Stock, LLC","relationship":"publisher joint-venture partner"},{"name":"Creative Direct Marketing Group","relationship":"paid promoter of Conexeu"},{"name":"Quote Daddy / Luxor IQ","relationship":"affiliated product promoted in article"},{"name":"MarketsandMarkets","relationship":"market research source"}],"dollarAmounts":[{"amount":"$13.37 billion","context":"global advanced wound care market value in 2025"},{"amount":"$19.32 billion","context":"projected wound care market value by 2030"},{"amount":"$69.7 million","context":"Axogen Q2 2026 revenue"},{"amount":"$279 million","context":"Axogen raised FY2026 revenue guidance floor"},{"amount":"$2.2 billion","context":"Solventum Q2 2026 sales"},{"amount":"$537 million","context":"Solventum Advanced Wound Care Q2 sales"},{"amount":"$77.5 million","context":"Vericel Q2 2026 revenue"},{"amount":"$200 million","context":"Vericel share repurchase authorization"},{"amount":"$23.0 billion","context":"Eli Lilly Q2 2026 revenue"},{"amount":"$85.0 billion to $87.0 billion","context":"Lilly raised FY2026 revenue guidance"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T13:06:10.378Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","paidContent":true,"eventGravity":"paid-promotion-commentary","issuerAuthored":false}},"durationMs":10003,"modelName":"glm-5.3-flashx"}}